Daily Respiratory Research Analysis
Analyzed 170 papers and selected 3 impactful papers.
Summary
Three impactful respiratory papers stand out: a prospective multicenter study shows an electrical-impedance-tomography–derived flow index during spontaneous breathing trials strongly predicts both SBT tolerance and early reintubation. A first-in-human randomized trial reports a fully liquid bivalent RSV–hMPV prefusion F vaccine with favorable safety and robust neutralization in older adults. A prospective diagnostic study demonstrates that structured aspirin challenge substantially improves detection of N-ERD in CRSwNP compared with history alone.
Research Themes
- Physiological monitoring and weaning readiness in critical care
- Multipathogen respiratory vaccination in older adults
- Improved diagnostic pathways for NSAID-exacerbated respiratory disease
Selected Articles
1. Electrical impedance tomography-derived flow index during spontaneous breathing trial stratifies the risk of reintubation within 48 h after extubation.
In a prospective multicenter study of 150 adults, an EIT-derived flow index (EFI) during a standardized pressure-support SBT showed excellent discrimination for SBT failure (AUC 0.980) and provided early warning of intolerance. Among 107 patients extubated after a successful SBT, all 48-hour reintubations occurred in those with EFI below 1.333, indicating residual physiological vulnerability despite SBT success.
Impact: This work introduces a practical, continuous, noninvasive index that bridges physiology and clinical decision-making, potentially reducing extubation failure by identifying high-risk patients who pass SBT.
Clinical Implications: EFI could complement SBT by flagging patients who need intensified post-extubation support, closer monitoring, or delayed extubation despite SBT success. Integration into weaning protocols may improve safety.
Key Findings
- EFI during SBT discriminated SBT failure with an AUC of 0.980.
- All early (≤48 h) reintubations after successful SBT occurred in patients with EFI < 1.333.
- EFI, RSBI, MIP, and P0.1 were each associated with 48-hour reintubation in univariable analyses.
Methodological Strengths
- Prospective multicenter design with standardized 30-minute pressure-support SBT and continuous EIT monitoring
- Predefined thresholds and time-to-event analyses for 48-hour reintubation
Limitations
- Exploratory secondary endpoint with few reintubation events limited multivariable modeling
- External validation and protocolized clinical impact assessment were not performed
Future Directions: External validation of EFI thresholds, integration into weaning bundles with decision support, and interventional trials to test whether EFI-guided strategies reduce extubation failure.
BACKGROUND: Spontaneous breathing trial (SBT) is the standard test of readiness for liberation from invasive mechanical ventilation, but some patients who successfully complete SBT still experience early post-extubation failure. Inspiratory effort during SBT has emerged as an important physiological determinant of weaning tolerance and extubation outcome because it reflects the balance between ventilatory load and respiratory muscle capacity, yet its assessment often requires airway occlusions, dedicated ventilator algor
2. Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial.
In this randomized, observer-blind, placebo- and active-controlled phase 1 trial, the fully liquid bivalent RSV–hMPV preF vaccine (VXB-241) induced robust RSV-A/B and hMPV-A/B neutralizing responses at 1 month in older adults, with a clinically acceptable safety profile. At 240 μg, RSV neutralization exceeded that of licensed adjuvanted RSVPreF3, while hMPV titers rose only with VXB-241.
Impact: This is among the first clinical demonstrations of a ready-to-use bivalent RSV–hMPV vaccine in older adults, addressing a major unmet need with strong early immunogenicity versus a licensed comparator.
Clinical Implications: If efficacy is confirmed, a single liquid vaccine could simplify seasonal prevention of both RSV and hMPV in older adults. Early safety/reactogenicity supports advancing to larger efficacy trials.
Key Findings
- At 1 month, all active arms showed higher RSV-A/B and hMPV-A/B neutralizing titers than placebo.
- At 240 μg, geometric mean fold increases were 15.06 (RSV-A) and 8.07 (RSV-B), exceeding RSVPreF3 (10.81 and 4.91).
- Reactogenicity was mostly mild/transient; no safety signal observed across doses aside from higher reactogenicity at the highest dose.
Methodological Strengths
- Randomized, observer-blind, placebo- and active-controlled dose-ranging design
- Head-to-head immunogenicity comparison with licensed adjuvanted RSVPreF3 active control
Limitations
- Interim 1-month analysis without clinical efficacy endpoints
- Sample size modest and highest-dose reactogenicity may limit dose selection
Future Directions: Proceed to phase 2/3 efficacy trials, durability assessments, and co-administration studies; explore optimization of dose balancing immunogenicity and reactogenicity.
BACKGROUND: Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are important causes of acute respiratory tract disease in older adults. Multipathogen vaccines in ready-to-use liquid formulations are needed. VXB-241 is a recombinant RSV-hMPV unadjuvanted fully liquid vaccine candidate. METHODS: This ongoing first-in-human randomised, placebo- and RSV vaccine active-controlled, observer-blind, dose-ranging trial is being conducted in older adults aged 60-83 years preceded by a few sentinel younger adults aged 18-40 years. On day 1, older adults were randomised to receive one of six intramuscular treatments: VXB-241 at 60 μg (30 μg RSV preF +30 μg hMPV preF), 120 μg (60 + 60), 240 μg (120 + 120), or 480 μg (240 + 240), the licensed AS01 RESULTS: A total of 270 older adults were screened; 128 were randomised and completed the month-1 visit. Solicited adverse events occurred in 23.8% of placebo, 76.2% of RSVPreF3, and 35.0%-59.1% of VXB-241 recipients, with no dose-response effect among VXB-241 recipients, except at the highest dose level. Most reactions were mild and transient. Most unsolicited adverse events were unrelated to treatment. No safety signal was detected. At month 1, RSV-A, RSV-B, hMPV-A and hMPV-B neutralising antibody titres were higher than placebo in all active treatment arms. At the 240 μg VXB-241 dose level, geometric mean fold increases were 15.06 for RSV-A and 8.07 for RSV-B versus 10.81 for RSV-A and 4.91 for RSV-B after RSVPreF3 injection, and 7.50 for hMPV-A and 6.56 for hMPV-B, with negligible increases after RSVPreF3 injection. CONCLUSIONS: VXB-241 showed a clinically acceptable safety and reactogenicity profile and elicited strong neutralising immune responses against RSV and hMPV in older adults. Neutralising immune responses against RSV-A and RSV-B by VXB-241 were at least as good as those obtained with the licensed adjuvanted RSVPreF3 active control.
3. Diagnostic Role of Aspirin Challenge in NSAID-Exacerbated Respiratory Disease: A Prospective Single-Center Study in China.
In 190 CRSwNP patients, a standardized algorithm with intranasal then oral aspirin challenge increased N-ERD diagnoses from 10.0% (history alone) to 32.1%. Intranasal challenge had a high negative predictive value (94.2%), supporting its use as an initial test with low rates of mild exacerbations during testing.
Impact: The study provides pragmatic evidence that structured aspirin challenge substantially improves N-ERD detection beyond history, validating intranasal challenge as a safe, efficient first step.
Clinical Implications: Adopting intranasal-first aspirin challenge in CRSwNP evaluations can standardize N-ERD diagnosis, guide avoidance and desensitization strategies, and optimize anti-inflammatory therapy selection.
Key Findings
- N-ERD diagnosis increased to 32.1% with full protocol vs 10.0% by history alone.
- Intranasal aspirin challenge negative predictive value was 94.2% (129/137).
- Adverse events during intranasal challenge were infrequent and mild (1.75% mild asthma exacerbations).
Methodological Strengths
- Prospective application of a standardized EAACI-aligned diagnostic algorithm
- Sequential intranasal then oral challenge clarified test performance characteristics
Limitations
- Single-center design may limit generalizability
- Short-term diagnostic outcomes without long-term management follow-up
Future Directions: Multicenter validation, incorporation into routine CRSwNP pathways, and assessment of downstream impacts on therapy selection and exacerbation reduction.
PURPOSE: Epidemiological data on non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) remain unknown in most countries, especially China. Moreover, aspirin challenge tests are not yet routinely used in clinical practice. To address these gaps, this study aimed to evaluate the diagnostic value of the aspirin challenge in identifying N-ERD among Chinese patients with chronic rhinosinusitis with nasal polyps (CRSwNP), using the algorithm proposed by the latest European Academy of Allergy and Clinical Immunology position paper. METHODS: Patients with CRSwNP were evaluated through a standardized diagnostic protocol, including clinical history review, intranasal aspirin challenge (IAC), and, if IAC was negative, a subsequent oral aspirin challenge (OAC). RESULTS: Among 190 CRSwNP patients (49.5% with asthma), N-ERD was diagnosed in 61 (32.1%). Of these, 19 (10.0%) were diagnosed based on clinical history, while 42 (22.1%) were diagnosed by aspirin challenge. Among challenge-positive patients, 34 reacted to IAC and 8 to OAC. Of the 137 patients with negative IAC results, 129 were tested negative by a subsequent OAC, yielding a negative predictive value of 94.2% (129/137) for IAC in the diagnosis of N-ERD. Mild asthma exacerbations occurred in 3 of 171 patients (1.75%) during IAC, all of whom had moderate-to-severe asthma. CONCLUSIONS: This is the first study to report that 32.1% of Chinese CRSwNP patients were diagnosed with N-ERD when a full diagnostic protocol was applied, compared to 10.0% based on history alone. These findings emphasize the diagnostic value of aspirin challenge and support IAC as an initial tool in the evaluation of N-ERD in CRSwNP.